Last reviewed: June 9, 2026
Last updated: June 9, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide has transformed weight management for millions, yet individuals planning pregnancy often face unanswered questions about medication timing and fetal safety. Current animal reproduction studies show no direct teratogenic effects at therapeutic doses, but human pregnancy data remains limited, making informed decision-making with your healthcare provider critical before conception.
Current Safety Data on GLP-1 Drugs and Pregnancy
The FDA classifies semaglutide as Pregnancy Category C, meaning animal studies have not revealed adverse fetal effects, but controlled human trials are absent. Preclinical research in rats and rabbits at doses up to 45 times the human therapeutic dose showed no malformations, miscarriage, or developmental delays. However, this animal data cannot be directly extrapolated to human pregnancy, which is why most clinicians recommend discontinuing semaglutide before attempting conception to eliminate any theoretical risk.
Real-world pregnancy registries tracking women who conceived while using GLP-1 medications are still in early phases, with limited published outcomes available. Several case reports and small observational studies suggest that accidental exposure during early pregnancy has not produced clustered adverse outcomes, but sample sizes remain too small to establish definitive safety profiles. Your individual medical history, weight loss goals, and fertility timeline should guide the decision to continue, pause, or restart semaglutide with your obstetrician and primary care team.
Recommended Timeline: When to Stop Semaglutide Before Conception
Most reproductive endocrinologists suggest discontinuing semaglutide 2–3 months before attempting to conceive, allowing the medication to clear from your system and metabolic parameters to stabilize. Semaglutide has a half-life of approximately 7 days, meaning the drug reaches undetectable levels within 4–6 weeks; the 2–3 month buffer accounts for metabolic adjustment and pregnancy test confirmation timing. Stopping earlier is not necessary from a pharmacokinetic standpoint but gives you psychological confidence and time to establish baseline weight and glucose patterns before conception.
If you are currently taking semaglutide at PlexusDx and planning pregnancy within the next 3–6 months, discuss a tapering schedule with your prescribing provider to avoid rebound appetite or rapid weight gain. Pausing semaglutide does not require a dose-down period—you simply stop the injections—but planning your discontinuation in advance allows time to build behavioral strategies for maintaining weight loss through diet and exercise alone during your fertility window.
Weight Management Strategies During Fertility Planning
Maintaining your pre-conception weight loss gains without semaglutide requires shifting focus to sustainable nutrition and activity habits you can sustain throughout pregnancy and lactation. A registered dietitian specializing in fertility can help you design a balanced, nutrient-dense eating pattern that supports ovulation, hormone regulation, and fetal development once pregnancy occurs. Many people find that the behavioral changes learned during semaglutide therapy—portion awareness, protein prioritization, and blood sugar stability—continue naturally even after medication discontinuation.
Exercise during the fertility-planning phase offers metabolic, emotional, and reproductive benefits: regular physical activity improves insulin sensitivity, supports healthy BMI ranges, and reduces stress hormones that may interfere with ovulation. Evidence shows that moderate-intensity activity (150 minutes weekly) in people with overweight or obesity enhances ovulatory function and fertility outcomes. PlexusDx encourages you to work with your fertility team and a movement specialist to design a pregnancy-safe exercise plan you can implement the moment conception occurs.
Personalized Fertility Planning with PlexusDx Precision Peptide Testing
PlexusDx offers a Precision Peptide Genetic Test that maps 14 metabolic pathways, 49 peptide hormones, and 150+ genetic insights—including variants in GLP1R, GIPR, FTO, and MC4R genes that influence appetite regulation and weight loss response. Understanding your unique genetic predispositions can inform not only your semaglutide dosing and treatment duration but also your baseline metabolic risk and long-term weight maintenance strategy after stopping the medication. Genetic insights help explain why some individuals experience robust weight loss with GLP-1 therapy while others require dose adjustments or combination approaches.
If you're planning to discontinue semaglutide for conception, the Precision Peptide Genetic Test ($99 add-on after your first month of treatment) provides a personalized roadmap for sustaining weight loss through behavioral, nutritional, and potentially alternative pharmacological approaches during your pregnancy planning window. This test is not pharmacogenomic screening; rather, it identifies your peptide-pathway biology to predict which interventions will work best for your individual metabolism, giving your fertility and weight management teams actionable, science-backed guidance.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Should I stop semaglutide immediately if I'm trying to conceive?
No—stopping abruptly can cause metabolic rebound and appetite surge. Instead, discuss a planned discontinuation 2–3 months before attempting conception with your doctor. This timeline allows semaglutide to clear from your system, your metabolism to adjust, and your fertility window to align with medication-free status.
Is semaglutide safe during pregnancy if I accidentally conceive?
Animal reproductive studies show no teratogenic effects at therapeutic doses, but controlled human pregnancy data is limited. If unplanned pregnancy occurs during semaglutide use, contact your obstetrician immediately—do not stop suddenly—and discuss risks and benefits for your specific situation. Most experts recommend discontinuing once pregnancy is confirmed.
Will I regain weight after stopping semaglutide before conception?
Weight regain risk varies by individual genetics and behavioral anchors established during treatment. PlexusDx Precision Peptide Genetic Test identifies your FTO, MC4R, and GLP1R variants to predict maintenance challenge and guide nutritional and activity strategies that support sustained results through pregnancy planning.
How does semaglutide affect fertility or ovulation?
Semaglutide itself does not directly suppress fertility, but significant weight loss can restore ovulatory function in people with obesity-related anovulation. Some users report altered appetite signals that may shift eating patterns; stopping the medication 2–3 months before conception allows reproductive hormone cycles to fully stabilize before attempting pregnancy.
Can PlexusDx help me plan medication timing around conception?
PlexusDx prescribers work with you to coordinate semaglutide discontinuation timelines with your fertility plan. The Precision Peptide Genetic Test ($99 add-on) reveals your metabolic pathway biology, helping predict how well you'll maintain weight loss off semaglutide and informing alternative strategies during your pregnancy-planning window.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Does Ozempic Work the First Week? Navigating Expectations for Weight Loss and Health
What Happens If Semaglutide Compound Is Not Refrigerated?